Given our findings that rs13900 modulates HuR binding and thereby influences CCL2 expression, targeting HuR-ARE interactions could offer a promising therapeutic avenue for conditions involving heightened monocyte/macrophage recruitment, such as inflammatory, cardiovascular, and neoplastic diseases. The gene discussed is ELAVL1; the disease is neoplasm.